Compile Data Set for Download or QSAR
Report error Found 355 Enz. Inhib. hit(s) with all data for entry = 10394
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532643(US11214565, Example A-52)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532648(US11214565, Example A-57)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532775(US11214565, Example D-18)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532777(US11214565, Example D-20)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532780(US11214565, Example D-62 | US11214565, Example D-2...)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532652(US11214565, Example A-62 | US11214565, Example A-6...)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532628(US11214565, Example A-37)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532758(US11214565, Example D-1)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532629(US11214565, Example A-38)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532760(US11214565, Example D-3)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532888(US11214565, Example D-142)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532762(US11214565, Example D-5)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532633(US11214565, Example A-42)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532765(US11214565, Example D-8)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532640(US11214565, Example A-49)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532929(US11214565, Example D-188)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532780(US11214565, Example D-62 | US11214565, Example D-2...)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532679(US11214565, Example A-88)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532814(US11214565, Example D-68)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532813(US11214565, Example D-67)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532657(US11214565, Example A-66)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532916(US11214565, Example D-169)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532920(US11214565, Example D-173)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532663(US11214565, Example A-72)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532793(US11214565, Example D-36)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532667(US11214565, Example A-76)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532798(US11214565, Example D-47 | N2-(1-(5,6-dihydro-4H-p...)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532669(US11214565, Example A-78)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532841(US11214565, Example D-95)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532718(US11214565, Example C-16)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532717(US11214565, Example C-15)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532719(US11214565, Example C-17)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532818(US11214565, Example D-72)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532946(US11214565, Example D-205)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532692(US11214565, Example B-4)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532824(US11214565, Example D-92 | US11214565, Example D-7...)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532695(US11214565, Example B-7)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532697(US11214565, Example B-9)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532700(US11214565, Example B-12)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532702(US11214565, Example B-14)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532701(US11214565, Example B-13)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532737(US11214565, Example C-35)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532613(US11214565, Example A-22)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532872(US11214565, Example D-126)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532618(US11214565, Example A-27)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532624(US11214565, Example A-33)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532623(US11214565, Example A-32)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532595(US11214565, Example A-3)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532601(US11214565, Example A-10)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM532604(US11214565, Example A-13)
Affinity DataIC50: 30nMAssay Description:50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT, 5 nM LRRK2, 134 μM ATP, 60 minute reaction time, 23° C. reaction temperature...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2022
Entry Details
US Patent

Displayed 1 to 50 (of 355 total ) | Next | Last >>
Jump to: